A new study from researchers at The University of Texas MD Anderson Cancer Center has uncovered how one of the most common ...

Dr. Priya Hays discusses the mechanisms of treatment resistance in cancer, highlighting their significance for developing ...

Scientists at MD Anderson Cancer Center have revealed how ATRX mutations restructure chromatin and activate oncogenic ...

The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.

What Is Hernexeos, and Why Does It Matter? Hernexeos (zongertinib) is a prescription medicine known as a kinase inhibitor that is used for treating adults with advanced non-small-cell lung cancer ...

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma Recurrent nonkinase domain FGFR VUS variants were collected from the Catalog of Somatic Mutations in Cancer and their ...

Mutations that accumulate in blood cells with age and raise the risk of leukemia and lymphoma can also colonize the brain’s ...

Researchers identified VIP inhibitory neurons in Huntington’s disease and used optogenetics to restore motor neuron activity in mice.